News & Updates

A once-daily dose of oral baricitinib may encourage hair regrowth in patients with severe alopecia areata, according to results of the phase III BRAVE-AA studies presented at AAD 2022.

Asivatrep cream improves clinical signs and symptoms of atopic dermatitis without causing worrying adverse events, reports a recent study.

PF-06826647, a novel tyrosine kinase 2 inhibitor in development, outperforms placebo at reducing disease severity in patient with moderate-to-severe plaque psoriasis, reveals a new trial.

Ritlecitinib and brepocitinib lead to improvements in scalp alopecia areata and its associated biomarkers, reveals a recent substudy of a phase 2a trial.

Use of microneedling appears to be a beneficial adjunct to topical medications in the treatment of melasma, suggests a recent study.

Rescue therapy using the Janus kinase 1 inhibitor abrocitinib combined with topical medicated therapy recaptured efficacy responses and had a favourable safety profile in individuals with moderate-to-severe atopic dermatitis (AD) who experienced flare during the maintenance period of the phase III randomized-withdrawal JADE REGIMEN trial.